What is the treatment for Raynaud's phenomenon?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Raynaud's Phenomenon

Calcium channel blockers, particularly nifedipine, are the first-line pharmacological treatment for Raynaud's phenomenon, with phosphodiesterase-5 inhibitors and prostacyclin analogues as second and third-line options respectively. 1, 2

Non-Pharmacological Management

  • Avoidance of known triggers is essential for all patients with Raynaud's phenomenon, including cold exposure, trauma, stress, smoking, vibration injury, and certain drugs (e.g., bleomycin, clonidine, ergot alkaloids) 1, 2
  • Wearing proper warm clothing in cold conditions is strongly recommended, including coat, mittens, hat, insulated footwear, and hand/foot warmers 1, 2
  • Physical therapy to stimulate blood flow and exercises to generate heat can help prevent symptom onset 1, 2
  • Smoking cessation strategies should be implemented as tobacco use worsens symptoms 1, 3

Pharmacological Treatment Algorithm

First-Line Therapy

  • Calcium channel blockers (CCBs), particularly nifedipine, are the most prescribed and studied medications for Raynaud's phenomenon 1, 2, 3
  • CCBs effectively reduce both frequency and severity of Raynaud's attacks 2, 4

Second-Line Therapy

  • Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil) should be considered when calcium channel blockers provide inadequate response 1, 2
  • PDE5 inhibitors effectively reduce frequency and severity of attacks and are beneficial for both healing and preventing digital ulcers 1, 2
  • Cost and off-label use may limit PDE5 inhibitor utilization 1

Third-Line Therapy

  • Intravenous prostacyclin analogues (e.g., iloprost) should be considered for severe Raynaud's phenomenon unresponsive to oral therapies 1, 2, 3
  • Prostacyclin analogues are effective for both healing and preventing digital ulcers 1

Management of Digital Ulcers

  • For prevention of new digital ulcers, especially in systemic sclerosis, bosentan (an endothelin receptor antagonist) is effective, particularly in patients with multiple digital ulcers 1, 2, 4
  • PDE5 inhibitors and prostacyclin analogues can be used for both healing and prevention of digital ulcers 1, 2
  • Wound care by specialized healthcare providers is important when ulcers develop 1
  • Antibiotics should be added only when infection is suspected 1
  • In severe cases with gangrene or osteomyelitis, amputation might be required 1, 2

Additional Treatment Options

  • Topical nitrates can be used as ancillary treatment 1, 4
  • Small trials support the use of botulinum toxin injections for healing and prevention of digital ulcers 1, 5
  • Digital sympathectomy may be considered for digital ulcer healing and prevention in refractory cases 1
  • Atorvastatin showed potential for preventing new digital ulcers in a small trial but is not included in major guidelines 1
  • Fat grafting has shown promise for healing digital ulcers in small trials 1

Primary vs. Secondary Raynaud's Considerations

  • Primary Raynaud's is typically milder and may require only non-pharmacological measures 2, 5
  • Secondary Raynaud's, particularly when associated with systemic sclerosis, often requires more aggressive pharmacological therapy 2, 6
  • Secondary Raynaud's has higher risk of complications including digital ulcers, gangrene, and osteomyelitis 1, 2

Treatment Efficacy and Limitations

  • Most pharmacological treatments reduce the severity and frequency of attacks but do not completely eliminate them 3
  • Many drugs are effective in less than 50% of treated patients 3
  • Regular monitoring is essential, particularly in patients with secondary Raynaud's, to detect and manage complications early 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Causes and Associations of Raynaud's Phenomenon

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Raynaud's Syndrome: a neglected disease.

International angiology : a journal of the International Union of Angiology, 2016

Research

Part II: The treatment of primary and secondary Raynaud's phenomenon.

Journal of the American Academy of Dermatology, 2024

Guideline

Raynaud's Phenomenon Involvement and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.